References
- GOLD [homepage on the Internet]Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2015 Available from: http://www.goldcopd.com/Accessed on March 10, 2015
- BlanchetteCMDalalAAMapelDChanges in COPD demographics and costs over 20 yearsJ Med Econ20121561176118222812689
- DalalAAChristensenLLiuFRiedelAADirect costs of chronic obstructive pulmonary disease among managed care patientsInt J Chron Obstruct Pulmon Dis2010534134921037958
- PatelJGNagarSPDalalAAIndirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United StatesInt J Chron Obstruct Pulmon Dis2014928930024672234
- BlanchetteCMGrossNJAltmanPRising costs of COPD and the potential for maintenance therapy to slow the trendAm Health Drug Benefits2014729810624991394
- ACCP/ATS Pulmonary Measure Gap Task Force [webpage on the Internet]Measure Gap Areas in Pulmonary Medicine: position paper2012 Available from: http://www.chestnet.org/Guidelines-and-Resources/Health-Policy/Position-PapersAccessed July 9, 2015
- KahnJMGouldMKKrishnanJAATS Ad Hoc Committee on the Development of Performance Measures from ATS GuidelinesAn official American thoracic society workshop report: developing performance measures from clinical practice guidelinesAnn Am Thorac Soc2014114S186S19524828810
- CantrellCRPriestJLCookCLFinchamJBurchSPAdherence to treatment guidelines and therapeutic regimens: a US claims-based benchmark of a commercial populationPopul Health Manag2011141334121142978
- National Quality Measures Clearinghouse [webpage on the Internet]Chronic obstructive pulmonary disease (COPD): hospital 30-day, all-cause, risk-standardized readmission rate following acute exacerbation of COPD hospitalization2014 Available from: http://www.qualitymeasures.ahrq.gov/content.aspx?id=48201Accessed October 6, 2015
- Department of Health and Human Sciences USACenters for Medicare and Medicaid ServicesFederal Register79 Book 2 of 2 Books49853505362014 Available from: https://www.gpo.gov/fdsys/pkg/FR-2014-08-22/pdf/2014-18545.pdfAccessed on October 6, 201525167590
- CalverleyPMAndersonJACelliBTORCH InvestigatorsSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
- TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
- HananiaNAOptimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomesClin Ther200729102121212318042470
- DalalAAShahMBD’SouzaAODhamaneADCraterGDOutcomes associated with timing of maintenance treatment for COPD exacerbationAm J Manag Care2012189e338e34523009332
- GOLD [homepage on the Internet]Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease2014 Available from: http://www.goldcopd.com/Accessed October 7, 2014
- Centers for Disease Control and Prevention [webpage on the Internet]International Classification of Diseases, Ninth Revision, Clinical Modification2011 Available from: http://www.cdc.gov/nchs/icd/icd9cm.htm#ftpAccessed August 4, 2015
- US Bureau of Labor Statistics [webpage on the Internet]Consumer Price Index2013 Available from: http://www.bls.gov/cpi/Accessed June, 2013
- BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J Suppl20034146s53s12795331
- ManningWGMullahyJEstimating log models: to transform or not to transform?J Health Econ200120446149411469231
- DuanNSmearing estimate: a non-parametric retransformation methodJ Am Stat Assoc198378383605610
- RomanoPSRoosLLJollisJGAdapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectivesJ Clin Epidemiol1993461010751079 discussion 1081–10908410092
- CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
- HurstJRVestboJAnzuetoAEvaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
- DonaldsonGCSeemungalTABhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
- MakrisDMoschandreasJDamianakiAExacerbations and lung function decline in COPD: new insights in current and ex-smokersRespir Med200710161305131217112715
- DecramerMCelliBKestenSLystigTMehraSTashkinDPEffect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trialLancet200937496961171117819716598
- JenkinsCRJonesPWCalverleyPMEfficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyRespir Res2009105919566934
- Jahnz-RozykKSzepielPEarly impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational studyInt J Chron Obstruct Pulmon Dis20151061362325834420
- CrinerGJBourbeauJDiekemperRLPrevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society GuidelineChest2015147489494225321320
- MakeBDutroMPPaulose-RamRMartonJPMapelDWUnder-treatment of COPD: a retrospective analysis of US managed care and Medicare patientsInt J Chron Obstruct Pulmon Dis201271922315517
- ShrankWHPatrickARBrookhartMAHealthy user and related biases in observational studies of preventive interventions: a primer for physiciansJ Gen Intern Med201126554655021203857